Search

Showing total 2 results
2 results

1. Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review.

Author

Setti, Giacomo, Pezzi, Margherita E., Viani, Maria Vittoria, Pertinhez, Thelma A., Cassi, Diana, Magnoni, Cristina, Bellini, Pierantonio, Musolino, Antonino, Vescovi, Paolo, and Meleti, Marco

Subjects
CANCER diagnosis, META-analysis, MICRORNA, TUMOR markers, PANCREATIC cancer
Abstract

Background: The aberrant expression of microRNAs (miRNAs) has been associated with several diseases, including cancer, inflammatory, and autoimmune conditions. Interest in salivary miRNAs as non-invasive tools for the diagnosis of malignancies and systemic diseases is rapidly increasing. The present systematic review was developed for answering the question: "Are salivary microRNAs reliable biomarkers for diagnosis of cancer and systemic diseases?" Methods: The application of inclusion and exclusion criteria led to the selection of 11 papers. Critical appraisals and quality assessments of the selected studies were performed through the National Institute of Health "Study Quality Assessment Tool" and the classification of the Oxford Center for Evidence-Based Medicine. Results: Seven studies reported statistically significant correlations between one or more salivary miRNAs and the investigated disease. The critical analysis allowed us to classify only two studies (18.2%) as having "good" quality, the rest being scored as "intermediate" (8; 73%) and "poor" (1; 9%). Evidence exists that salivary miR-940 and miR-3679-5p are reliable markers for pancreatic cancer and that miR140-5p and miR301a are promising molecules for the salivary diagnosis of gastric cancer. Conclusions: Further studies, possibly avoiding the risk of bias highlighted here, are necessary to consolidate these findings and to identify new reliable salivary biomarkers. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

2. Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review

Author

Diana Cassi, Antonino Musolino, Pierantonio Bellini, Cristina Magnoni, Marco Meleti, Giacomo Setti, Margherita Eleonora Pezzi, Maria Vittoria Viani, Thelma A. Pertinhez, and Paolo Vescovi

Subjects
Oncology, medicine.medical_specialty, Saliva, diagnosis, MEDLINE, Disease, Review, Catalysis, Autoimmune Diseases, Inorganic Chemistry, lcsh:Chemistry, Internal medicine, Pancreatic cancer, Neoplasms, microRNA, Biomarkers, Cancer, Diagnosis, MiRNA, Medicine, Humans, cancer, Inflammation, MicroRNAs, Physical and Theoretical Chemistry, Molecular Biology, lcsh:QH301-705.5, Spectroscopy, saliva, Study quality, business.industry, Organic Chemistry, biomarkers, General Medicine, medicine.disease, Computer Science Applications, lcsh:Biology (General), lcsh:QD1-999, Inclusion and exclusion criteria, business, mirna
Abstract

Background: The aberrant expression of microRNAs (miRNAs) has been associated with several diseases, including cancer, inflammatory, and autoimmune conditions. Interest in salivary miRNAs as non-invasive tools for the diagnosis of malignancies and systemic diseases is rapidly increasing. The present systematic review was developed for answering the question: “Are salivary microRNAs reliable biomarkers for diagnosis of cancer and systemic diseases?” Methods: The application of inclusion and exclusion criteria led to the selection of 11 papers. Critical appraisals and quality assessments of the selected studies were performed through the National Institute of Health “Study Quality Assessment Tool” and the classification of the Oxford Center for Evidence-Based Medicine. Results: Seven studies reported statistically significant correlations between one or more salivary miRNAs and the investigated disease. The critical analysis allowed us to classify only two studies (18.2%) as having “good” quality, the rest being scored as “intermediate” (8; 73%) and “poor” (1; 9%). Evidence exists that salivary miR-940 and miR-3679-5p are reliable markers for pancreatic cancer and that miR140-5p and miR301a are promising molecules for the salivary diagnosis of gastric cancer. Conclusions: Further studies, possibly avoiding the risk of bias highlighted here, are necessary to consolidate these findings and to identify new reliable salivary biomarkers.

Published
2020